Analgesic composition of topically applied nonsteroidal antiinflammatory drugs and opioids
The attractiveness of this combinations is their propensity to suppress the expression and function of proteins involved in inflammatory and neuropathic pain and in the same time to activate the antinociceptive mu opiod system involved in pain relief. Targeting the different system, pro-nociceptive and anti-nociceptive, result in summation of the analgesic effects.
The European neuropathic pain market is characterized by a particularly high level of unmet need for effective therapeutics due to the under-utilization of anti-depressants, the lack of opioid availability, commonly used to treat neuropathic pain in the U.S. and certain European country-markets, but not others. This under-utilization stems primarily from a lack of awareness about the potential utility of these drugs in neuropathic pain treatment and concerns about opioid addiction. By 2015, the
US20080449912
Germany, UK, France, Italy, Sweden, Swiss,Ireland, Canada, 13. Pending USA, India
Sale, License agreement
Issued patent
丹麥
